Hospital Research studies

Kaiser Permanente’s diverse Southern California membership, our electronic medical record, and our integrated care model provide the ideal environment for our researchers to study and develop ways of improving hospital care. Some of our studies have evaluated strategies to help reduce the chance that patients will be readmitted to the hospital and assessed the safety of seasonal flu vaccination for surgical patients.

Kaiser Permanente Southern California and Novavax Collaboration on RSV Epidemiology

The purpose of this study is to provide critical information about the predictors of severe RSV disease, describe epidemiology and burden of hospitalized RSV disease in older adults, and assess healthcare utilization associated with hospitalized RSV disease in older adults in a community setting. A population of hospitalized older adults testing positive for influenza will also be identified for comparison purposes.

Principal Investigator:

Hung Fu Tseng, PhD, MPH

Funding Source:

Novavax, Inc.

Funding Years:

2016 - 2018

Post-licensure observational safety surveillance study of quadrivalent meningococcal ACWY conjugate vaccine

This study is an observational post-marketing safety study required by the United States Food and Drug Administration (FDA). The primary objective of this study is to describe medical events that require emergency room visit or hospitalization in 6 months following MenACWY-CRM vaccination in children 2-23 months of age in a health maintenance organization (HMO) in the United States.

Principal Investigator:

Hung Fu Tseng, PhD, MPH

Funding Source:

Novartis Vaccines and Diagnostics, Inc.

Funding Years:

2014 - 2018

Utilizing Real World Data to Describe Clinical and Safety Outcomes Among Hospitalized COVID-19 Patients, and to Create a Comparator Arm for a Randomized Controlled Trial Evaluating the Efficacy and Safety of Actemra for COVID-19 Patients

Elevated tissue and serum levels of IL-6 have been implicated in the disease pathology of several inflammatory and autoimmune disorders including rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA), and cytokine-release syndrome (CRS). Tocilizumab or TCZ (Actemra) is a recombinant humanized, anti-human monoclonal antibody directed against soluble and membrane-bound IL-6R. On March 3rd 2020, TCZ was included in the updated diagnosis and treatment plan for COVID-19 issued by the China National Health Commission as one treatment option for severe or critical forms of COVID-19 pneumonia. However, despite fairly widespread use in China, Actemra has not received health authority approval for COVID-19 in any country. More robust clinical evidence regarding the safety or efficacy of TCZ in the treatment of COVID-19 is needed. Roche is conducting a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of TCZ in combination with SOC compared with matching placebo in combination with SOC in hospitalized adult patients with severe COVID-19 pneumonia (n=330). KPSC is collecting demographic, comorbidity, and clinical information on KPSC patients hospitalized with COVID-19 infection to create a real world data (RWD) comparator arm that will be matched to the TCZ treatment arm of the RCT.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

Genentech, Inc.

Funding Years:

2020